Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

AbbVie Inc. ABBV

Set alert

Price alert · ABBV

All alert types
287.19 USD -1.65 -0.57%

As of Nov 3, 2:07 PM ET

Bid
287.19 × 1
Ask
287.28 × 1
286.91 Day range 291.32
197.38 52-week range 294.89
YTD
+25.69%
1 year
+35.49%
Open
288.69
Prev close
288.84
Mkt cap
507.96B
Vol
2.13M
Avg vol
4.74M
EPS
5.82
P/E
49.39
Div yield
2.38%
More statistics
Low
286.91
High
291.32
Forward P/E
17.88
Beta
0.19
Short ratio
3.22
Inst. own
77.39%
Dividend
6.92
Ex-div date
Jan 14, 2027
Earnings
Feb 3, 2027
50-d avg
269.29
200-d avg
237.10
1y target
298.50

1M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Oct 15, 2026Dividend: 1.73
  • Oct 30, 2026Earnings: 3.82; estimate 3.73; surprise 2.41%
  • Nov 2, 2026Rating: Canaccord Genuity · Buy → Buy
  • Nov 2, 2026Rating: RBC Capital · Outperform → Outperform
  • Nov 2, 2026Rating: Wells Fargo · Overweight → Overweight
  • Nov 2, 2026Rating: Guggenheim · Buy → Buy
  • Nov 2, 2026Rating: Morgan Stanley · Overweight → Overweight
  • Nov 2, 2026Rating: Leerink Partners · Outperform → Outperform
Signals (7)
NameDateAgo
MACD: Sell SignalNov 3, 20264 hours ago
RSI: OverboughtOct 30, 20264 days ago
RSI: OverboughtOct 20, 20262 weeks ago
RSI: OverboughtOct 16, 20262 weeks ago
RSI: OverboughtOct 9, 20263 weeks ago
MACD: Buy SignalOct 7, 20263 weeks ago
SMA: BullishOct 5, 20264 weeks ago

Analyst view

Consensus: buy

Buy
Price target (mean) 298.50 +3.9% upside
Target (low)
200.00
Target (mean)
298.50
Target (high)
350.00
Ratings (0m) 29 23 buy · 5 hold · 1 sell
  • Strong buy7
  • Buy16
  • Hold5
  • Sell0
  • Strong sell1

Recommendation trend

  • This month 29
  • 1 month ago 29
  • 2 months ago 30
  • 3 months ago 31

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ABBV analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter3.893.84 – 4.012.71+43.6%18.41B+10.8%18
Next quarter3.453.30 – 3.902.65+30.1%16.43B+9.6%8
Current year14.0013.93 – 14.1310.00+40.0%67.82B+10.9%22
Next year16.1815.17 – 17.2314.00+15.6%73.79B+8.8%28

Upgrades and downgrades

The latest rating changes

ABBV analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026Leerink PartnersMaintainedOutperformOutperform
Nov 2, 2026Morgan StanleyMaintainedOverweightOverweight
Nov 2, 2026GuggenheimMaintainedBuyBuy
Nov 2, 2026Wells FargoMaintainedOverweightOverweight
Nov 2, 2026RBC CapitalMaintainedOutperformOutperform
Nov 2, 2026Canaccord GenuityMaintainedBuyBuy
Nov 2, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Oct 23, 2026Goldman SachsMaintainedNeutralNeutral
Oct 21, 2026BarclaysMaintainedOverweightOverweight
Oct 13, 2026RBC CapitalReiteratedOutperformOutperform
Oct 9, 2026UBSMaintainedNeutralNeutral
Oct 9, 2026GuggenheimReiteratedBuyBuy
Oct 8, 2026JP MorganMaintainedOverweightOverweight
Oct 8, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Oct 7, 2026Morgan StanleyMaintainedOverweightOverweight
Oct 6, 2026ScotiabankMaintainedSector OutperformSector Outperform
Sep 10, 2026HSBCMaintainedBuyBuy
Aug 20, 2026Piper SandlerMaintainedOverweightOverweight
Aug 17, 2026Wells FargoMaintainedOverweightOverweight
Aug 13, 2026Wolfe ResearchUpgradePeer PerformOutperform
Aug 11, 2026BNP ParibasMaintainedNeutralNeutral
Aug 10, 2026Evercore ISI GroupMaintainedOutperformOutperform
Aug 6, 2026BerenbergMaintainedBuyBuy
Aug 5, 2026Erste GroupUpgradeHoldBuy
Aug 4, 2026GuggenheimMaintainedBuyBuy
Aug 3, 2026Canaccord GenuityMaintainedBuyBuy
Aug 3, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Aug 3, 2026Morgan StanleyMaintainedOverweightOverweight
Jul 31, 2026TD CowenMaintainedBuyBuy
Jul 31, 2026William BlairMaintainedBuyBuy